which has thus become one of the most important means we have for investigating molecular structure. There is, indeed, no experimental method that gives more detailed information on this subject.

Impact and progress Frontiers' impact Progress Report 2022 All progress reports ...

Extended-interval dosing (EID) of ocrelizumab offers patients with multiple sclerosis (MS ... Juliana Campos (MSc, PhD) is a freelance writer with a strong scientific background in biomedicine, ...

Jan. 23, 2025 — Researchers have uncovered which genes on the Y chromosome regulate the development of sperm and impact fertility in male mice. This research could help us understand why some ...

Often known as the central science, it is a creative discipline chiefly concerned with atomic and molecular structure and its change, for instance through chemical reactions. Observations of salt ...

The Department of Biochemistry and Molecular Pharmacology at NYU Langone Health has a rich and distinguished history and maintains active research programs in epigenetics, genome integrity, protein ...

Chemical engineers are problem solvers - they bring new medicines to market, develop alternative fuels, keep food manufacturing safe, and create new manufacturing materials. They move small-scale ...

Jan. 27, 2025 — An international team of scientists has discovered a way to store and release volatile hydrogen using lignin-based jet fuel that could open new pathways for sustainable energy ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.

Institute of Materials for Electronics and Energy Technology (i-MEET), Department of Materials Science and Engineering, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Martensstraße 7, 91058 ...

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

This study investigates the potential clinical synergy between the PARP inhibitor niraparib (Zejula) and concomitant statins, exploring their combined effects on progression-free survival (PFS) in ...